1. Search Result
Search Result
Results for "

BSI

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

3

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12015
    Iniparib
    5+ Cited Publications

    BSI-201; NSC-746045; IND-71677

    PARP Influenza Virus Cancer
    Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.
    Iniparib
  • HY-P990906

    BSI-045B; TQC2731

    Interleukin Related Inflammation/Immunology
    Bosakitug (BSI-045B) is an TSLP-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Bosakitug can be used in the research of inflammatory diseases such as moderate to severe atopic dermatitis .
    Bosakitug
  • HY-P991364

    PYX-106; BSI-060T

    Transmembrane Glycoprotein Cancer
    Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Aldastotug
  • HY-108238

    PARP Cancer
    BSI-401 is an orally active PARP-1 inhibitor. BSI-401 alone and in synergism with Oxaliplatin (HY-17371) inhibits pancreatic cancer .
    BSI-401
  • HY-12015R

    BSI-201 (Standard); NSC-746045 (Standard); IND-71677 (Standard)

    PARP Influenza Virus Reference Standards Cancer
    Iniparib (Standard) is the analytical standard of Iniparib. This product is intended for research and analytical applications. Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.
    Iniparib (Standard)
  • HY-P991977

    5G9

    EGFR Apoptosis PARP Akt ERK Cancer
    BSI-001 (5G9) is a HER2-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of HER2-positive breast cancer and HER2-overexpressing gastric cancer .
    BSI-001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: